Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

Stopped early · Phase 1

Conditions studied: Central Nervous System Neoplasms, Neoplasm Metastasis

In brief

The goal of this study is to find the maximum dose of a drug, temozolomide, that can safely be given to subjects with brain tumors. Past studies showed that the maximum dose of temozolomide was limited by low blood counts. The investigators will use blood stem cells collected from bone marrow to help subjects recover their blood counts, a procedure called autologous stem cell transplant or stem cell rescue. This way, the investigators expect to be able to safely deliver very high doses of temozolomide. This study is only available at Tufts Medical Center.

Key facts

Study ID

NCT00629187

Run by

Tufts Medical Center

People needed

2

Starts

2004-04-01

Expected to finish

2012-04-01

Last updated by the study team

2012-04-27

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients or their health care proxies must be able to provide consent to participate in this trial.
• Patients must have one of the following diagnoses which has not responded or recurred following at least one prior chemotherapy regimen or radiation therapy:
• anaplastic astrocytoma, glioblastoma multiforme or oligodendroglioma
• primary CNS lymphoma
• malignant disease metastatic to the CNS
• Patients must be candidates for high dose chemotherapy and autologous stem cell transplant according to the following criteria:
• Patients must be between the ages of 18 and 70 years (inclusive)
• Patients must have a left ventricular ejection fraction greater than or equal to 45% by MUGA or echocardiogram
• Patients must have adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of predicted
• Patients must have serum direct bilirubin less than or equal to 2.0 mg/dl and transaminases less than or equal to 3x institutional upper limit of normal
• Patients must have serum creatinine less than or equal to 2 mg/dl with creatinine clearance greater than or equal to 60 ml/min (either calculated or measured)
• Patients must have an ECOG performance status between 0 and 2
• Patients must be at least 4 weeks from last cytoreductive chemotherapy.
• Expected survival of at least 3 months

You may not qualify if…

• Patients with uncontrolled metastatic disease outside of the CNS which would itself, in the investigator's opinion, limit survival to less than 6 months
• Patients with uncontrolled seizures are ineligible.
• Patients with a history of myocardial infarction within the preceding 6 months, significant arrhythmia within the preceding 3 months, or uncontrolled hypertension or congestive heart failure are ineligible.
• Patients with unstable angina are ineligible.
• Pregnant or lactating women are ineligible.
• Male and female patients who do not agree to practice approved methods of birth control for the duration of the study are ineligible.
• Patients with uncontrolled, active infection are ineligible.
• Patients infected with HIV are ineligible.

Where it is running

• Tufts Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.